Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 1Phase 1 1

Status

Active not recruiting 4Recruiting 3

Sponsor Class

OTHER 9INDUSTRY 7NIH 1NETWORK 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Genitourinary 7

Conditions

Prostatic Neoplasms 5Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castrate-sensitive Prostate Cancer 1

Interventions

pembrolizumab 131Carboplatin 106Paclitaxel 66Cisplatin 61Gemcitabine 57Pemetrexed 56Bevacizumab 50Docetaxel 47Fluorouracil 40Oxaliplatin 38Dexamethasone 34130-nm albumin-bound paclitaxel 34Leucovorin 33atezolizumab 32Cetuximab 32durvalumab 30Nivolumab 28Rituximab 26Cyclophosphamide 26Capecitabine 26Prednisone 25Fulvestrant 24enzalutamide 23Lenalidomide 22venetoclax 21Letrozole 20Irinotecan 20Doxorubicin 17ribociclib 16pomalidomide 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Androgen Antagonists × 30 days × Clear all
NCT02489318 2026-06-05

TITAN

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
1,052 enrolled 13 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT03767244 2026-06-05

PROTEUS

Janssen Research & Development, LLC

Phase 3 Active not recruiting
2,517 enrolled
Genitourinary

Prostatic Neoplasms

NCT04108208 2026-06-05

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Janssen Research & Development, LLC

Phase 4 Active not recruiting
75 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT05884398 2026-06-05

LIBERTAS

Janssen Research & Development, LLC

Phase 3 Active not recruiting
420 enrolled
Genitourinary

Metastatic Castrate-sensitive Prostate Cancer

NCT07570979 2026-05-28

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Novartis

Phase 1 Recruiting
208 enrolled
Genitourinary

Prostatic Neoplasms

NCT06661122 2026-05-19

HAYATE

Bayer

Recruiting
100 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06952803 2026-05-19

EvoPAR-PR02

AstraZeneca

Phase 3 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡